Samuel Dagogo-Jack

List of Publications by Year
in descending order

131 papers	8,861 citations	94415 37 h-index	43886 91 g-index

131 all docs	131 docs citations	131 times ranked	9751 citing authors

#	Article	IF	Citations
1	Racial and ethnic disparities associated with the measure for drug-drug interactions among Medicare beneficiaries. Journal of the American Pharmacists Association: JAPhA, 2022, 62, 142-149.	1.5	1
2	Severe Hypoglycemia and Incident Heart Failure Among Adults With Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e955-e962.	3.6	17
3	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. Journal of Diabetes and Its Complications, 2022, 36, 108101.	2.3	23
4	Plasma FGF-21 and Sclerostin Levels, Glycemia, Adiposity, and Insulin Sensitivity in Normoglycemic Black and White Adults. Journal of the Endocrine Society, 2022, 6, bvab183.	0.2	3
5	Cardiorenal outcomes with ertugliflozin assessed according to baseline glucoseâ€lowering agent: An analysis from <scp>VERTIS CV</scp>. Diabetes, Obesity and Metabolism, 2022, , .	4.4	5
6	Outcome of lifestyle intervention in relation to duration of pre-diabetes: the Pathobiology and Reversibility of Prediabetes in a Biracial Cohort (PROP-ABC) study. BMJ Open Diabetes Research and Care, 2022, 10, e002748.	2.8	6
7	Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 2022, 24, 1829-1839.	4.4	23
8	Role of ceramides in the pathogenesis of diabetes mellitus and its complications. Journal of Diabetes and Its Complications, 2021, 35, 107734.	2.3	48
9	Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes. JAMA Cardiology, 2021, 6, 148.	6.1	625
10	Gradient of Risk and Associations With Cardiovascular Efficacy of Ertugliflozin by Measures of Kidney Function. Circulation, 2021, 143, 602-605.	1.6	24
11	Risk Factors for Longitudinal Resting Heart Rate and Its Associations With Cardiovascular Outcomes in the DCCT/EDIC Study. Diabetes Care, 2021, 44, 1125-1132.	8.6	6
12	Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial. Diabetologia, 2021, 64, 1256-1267.	6.3	103
13	Predictive utilities of lipid traits, lipoprotein subfractions and other risk factors for incident diabetes: a machine learning approach in the Diabetes Prevention Program. BMJ Open Diabetes Research and Care, 2021, 9, e001953.	2.8	7
14	Genetic Risk Factors for CVD in Type 1 Diabetes: The DCCT/EDIC Study. Diabetes Care, 2021, 44, 1309-1316.	8.6	4
15	Association of plasma acylcarnitines with insulin sensitivity, insulin secretion, and prediabetes in a biracial cohort. Experimental Biology and Medicine, 2021, 246, 1698-1705.	2.4	4
16	Kidney outcomes using a sustained â‰¥40% decline in <scp>eGFR</scp>: A metaâ€analysis of <scp>SGLT2</scp> inhibitor trials. Clinical Cardiology, 2021, 44, 1139-1143.	1.8	20
17	Ertugliflozin and Slope of Chronic eGFR. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1345-1354.	4.5	26
18	Racial/ethnic disparities in measure calculations for Part D Star Ratings among Medicare beneficiaries with diabetes, hypertension, and/or hyperlipidemia. Research in Social and Administrative Pharmacy, 2021, 17, 1469-1477.	3.0	8

#	Article	IF	Citations
19	Cardiovascular outcomes of antidiabetes medications by race/ethnicity: A systematic review and meta-analysis. Journal of Diabetes and Its Complications, 2021, 35, 107980.	2.3	3
20	Exploring racial and ethnic disparities in medication adherence among Medicare comprehensive medication review recipients. Exploratory Research in Clinical and Social Pharmacy, 2021, 3, 100041.	1.0	2
21	Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial. BMJ Open Diabetes Research and Care, 2021, 9, e002484.	2.8	14
22	Trajectories of Body Weight and Fat Mass in Relation to Incident Prediabetes in a Biracial Cohort of Free-Living Adults. Journal of the Endocrine Society, 2021, 5, bvaa164.	0.2	5
23	Islet cell encapsulation â€“ Application in diabetes treatment. Experimental Biology and Medicine, 2021, 246, 2570-2578.	2.4	10
24	Association of history of heart failure with hospital outcomes of hyperglycemic crises: Analysis from a University hospital and national cohort. Journal of Diabetes and Its Complications, 2020, 34, 107466.	2.3	5
25	Efficacy of Ertugliflozin on Heart Failureâ€“Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease. Circulation, 2020, 142, 2205-2215.	1.6	156
26	Long-term metformin adherence in the Diabetes Prevention Program Outcomes Study. BMJ Open Diabetes Research and Care, 2020, 8, e001537.	2.8	14
27	Five-Year Glycemic Trajectories Among Healthy African-American and European-American Offspring of Parents With Type 2 Diabetes. American Journal of the Medical Sciences, 2020, 359, 266-270.	1.1	2
28	Calorie Restriction and Intermittent Fasting: Impact on Glycemic Control in People With Diabetes. Diabetes Spectrum, 2020, 33, 143-148.	1.0	4
29	Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. New England Journal of Medicine, 2020, 383, 1425-1435.	27.0	927
30	Regression from prediabetes to normal glucose regulation: State of the science. Experimental Biology and Medicine, 2020, 245, 889-896.	2.4	29
31	Multi-year reproducibility of hyperinsulinemic euglycemic clamp-derived insulin sensitivity in free-living adults: Association with incident prediabetes in the POP-ABC study. Metabolism: Clinical and Experimental, 2020, 109, 154263.	3.4	9
32	Pathobiology and Reversibility of Prediabetes in a Biracial Cohort (PROP-ABC) Study: design of lifestyle intervention. BMJ Open Diabetes Research and Care, 2020, 8, e000899.	2.8	3
33	Role of the HPA Axis in the Metabolic and Baroreflex Components of Hypoglycemia-Associated Autonomic Failure. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3466-e3468.	3.6	0
34	Glycemic Response to Oral Dexamethasone Predicts Incident Prediabetes in Normoglycemic Subjects With Parental Diabetes. Journal of the Endocrine Society, 2020, 4, bvaa137.	0.2	1
35	Genetic ancestry markers and difference in A1c between African-American and White in the Diabetes Prevention Program. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 328-336.	3.6	12
36	Regression From Prediabetes to Normal Glucose Regulation and Prevalence of Microvascular Disease in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes Care, 2019, 42, 1809-1815.	8.6	61

#	Article	IF	Citations
37	Biomarkers of insulin action during single soccer sessions before and after a 12-week training period in type 2 diabetes patients on a caloric-restricted diet. Physiology and Behavior, 2019, 209, 112618.	2.1	12
38	Metabolite Profiles of Incident Diabetes and Heterogeneity of Treatment Effect in the Diabetes Prevention Program. Diabetes, 2019, 68, 2337-2349.	0.6	22
39	A Polygenic Lipodystrophy Genetic Risk Score Characterizes Risk Independent of BMI in the Diabetes Prevention Program. Journal of the Endocrine Society, 2019, 3, 1663-1677.	0.2	13
40	Comparative Effectiveness of Medication Therapy Management Eligibility Criteria Across Racial/Ethnic Groups. Journal of the American Geriatrics Society, 2019, 67, 581-587.	2.6	3
41	Prevention begets prevention â€" lessons from the Da Qing Study. Nature Reviews Endocrinology, 2019, 15, 442-443.	9.6	5
42	Amino acid signature predictive of incident prediabetes: A case-control study nested within the longitudinal pathobiology of prediabetes in a biracial cohort. Metabolism: Clinical and Experimental, 2019, 98, 76-83.	3.4	27
43	Ethnic Disparities in Adiposity: Focus on Non-alcoholic Fatty Liver Disease, Visceral, and Generalized Obesity. Current Obesity Reports, 2019, 8, 243-254.	8.4	37
44	Long-term Effects of Metformin on Diabetes Prevention: Identification of Subgroups That Benefited Most in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. Diabetes Care, 2019, 42, 601-608.	8.6	82
45	Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study. Diabetes Care, 2019, 42, 657-664.	8.6	32
46	Response to Comment on Braffett et al. Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study. Diabetes Care 2019;42:657â€"664. Diabetes Care, 2019, 42, e137-e137.	8.6	0
47	Sickle Cell Trait, European Ancestry, and Longitudinal Tracking of HbA1c Among African Americans: The Jackson Heart Study. Diabetes Care, 2019, 42, e166-e167.	8.6	2
48	Awareness of Prediabetes Status and Subsequent Health Behavior, Body Weight, and Blood Glucose Levels. Journal of the American Board of Family Medicine, 2019, 32, 20-27.	1.5	17
49	Prediabetes and Cardiovascular Disease. Endocrinology and Metabolism Clinics of North America, 2018, 47, 33-50.	3.2	157
50	Diabetes Care in Nigeria. Annals of Global Health, 2018, 81, 821.	2.0	48
51	Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The <scp>VERTIS SITA2</scp> placeboâ€controlled randomized study. Diabetes, Obesity and Metabolism, 2018, 20, 530-540.	4.4	121
52	Predictive value positive of MTM eligibility criteria under MMA and ACA in identifying individuals with medication utilization issues. Journal of Pharmaceutical Health Services Research, 2018, 9, 393-401.	0.6	1
53	Physiology of Glycemic Recovery and Stabilization After Hyperinsulinemic Euglycemic Clamp in Healthy Subjects. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 4155-4162.	3.6	9
54	Higher Predictive Value Positive for MMA Than ACA MTM Eligibility Criteria Among Racial and Ethnic Minorities: An Observational Study. Inquiry (United States), 2018, 55, 004695801879574.	0.9	1

#	Article	IF	Citations
55	Racial and Ethnic Disparities in Meeting MTM Eligibility Criteria Based on Star Ratings Compared with the Medicare Modernization Act. Journal of Managed Care & Specialty Pharmacy, 2018, 24, 97-107.	0.9	6
56	Design and baseline characteristics of the eValuation of ERTugliflozin efficacy and Safety CardioVascular outcomes trial (VERTIS-CV). American Heart Journal, 2018, 206, 11-23.	2.7	171
57	Parental History of Type 2 Diabetes Abrogates Ethnic Disparities in Key Glucoregulatory Indices. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 514-522.	3.6	4
58	Parental history of type 2 diabetes is associated with lower resting energy expenditure in normoglycemic subjects. BMJ Open Diabetes Research and Care, 2018, 6, e000511.	2.8	7
59	Basal and Dynamic Leptin Secretion: Association with Cardiometabolic Risk and Body Weight Trajectories in African-Americans and European-Americans. Frontiers in Endocrinology, 2018, 9, 12.	3.5	3
60	Ethnic Disparities in Endothelial Function and Its Cardiometabolic Correlates: The Pathobiology of Prediabetes in A Biracial Cohort Study. Frontiers in Endocrinology, 2018, 9, 94.	3.5	8
61	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm â€“ 2018 Executive Summary. Endocrine Practice, 2018, 24, 91-121.	2.1	388
62	Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. Diabetes, Obesity and Metabolism, 2017, 19, 721-728.	4.4	113
63	Primary Prevention of Type 2 Diabetes: An Imperative for Developing Countries. , 2017, , 7-31.		3
64	Editorial: The continuum of dysglycemia: Predicting progression from prediabetes to type 2 diabetes. Journal of Diabetes and Its Complications, 2017, 31, 1249-1251.	2.3	1
65	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive type 2 Diabetes Management Algorithm â€“ 2017 Executive Summary. Endocrine Practice, 2017, 23, 207-238.	2.1	362
66	Relationships between blood pressure and blood glucose among offspring of parents with type 2 diabetes: Prediction of incident dysglycemia in a biracial cohort. Journal of Diabetes and Its Complications, 2017, 31, 1580-1586.	2.3	8
67	Insulin-sensitive and insulin-resistant obese and non-obese phenotypes: role in prediction of incident pre-diabetes in a longitudinal biracial cohort. BMJ Open Diabetes Research and Care, 2017, 5, e000415.	2.8	52
68	Hyperglycemic, high anion-gap metabolic acidosis in patients receiving SGLT-2 inhibitors for diabetes management. Journal of Diabetes and Its Complications, 2017, 31, 611-614.	2.3	15
69	2015 Presidential Address: 75 Years of Battling Diabetesâ€”Our Global Challenge. Diabetes Care, 2016, 39, 3-9.	8.6	15
70	American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the Association of SGLT-2 Inhibitors and Diabetic Ketoacidosis. Endocrine Practice, 2016, 22, 753-762.	2.1	242
71	Adiponectin levels predict prediabetes risk: the Pathobiology of Prediabetes in A Biracial Cohort (POP-ABC) study. BMJ Open Diabetes Research and Care, 2016, 4, e000194.	2.8	53
72	Plasma lipid levels predict dysglycemia in a biracial cohort of nondiabetic subjects: Potential mechanisms. Experimental Biology and Medicine, 2016, 241, 1961-1967.	2.4	20

#	Article	IF	Citations
73	Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Diabetes Care, 2016, 39, 1684-1692.	8.6	60
74	Prediabetes as a toxic environment for the initiation of microvascular and macrovascular complications. Experimental Biology and Medicine, 2016, 241, 1323-1331.	2.4	111
75	American Association Of Clinical Endocrinologists And American College Of Endocrinology -Clinical Practice Guidelines For Developing A Diabetes Mellitus Comprehensive Care Plan â€“ 2015. Endocrine Practice, 2015, 21, 1-87.	2.1	443
76	American Association of Clinical Endocrinologists and American College of Endocrinology â€“ Clinical Practice Guidelines for Developing A Diabetes Mellitus Comprehensive Care Plan â€“ 2015 â€” Executive Summary. Endocrine Practice, 2015, 21, 413-437.	2.1	359
77	Potential Health Implications of Medication Therapy Management Eligibility Criteria in the Patient Protection and Affordable Care Act Across Racial and Ethnic Groups. Journal of Managed Care & Specialty Pharmacy, 2015, 21, 993-1003.	0.9	9
78	Dietary habits and leisure-time physical activity in relation to adiposity, dyslipidemia, and incident dysglycemia in the pathobiology of prediabetes in a biracial cohort study. Metabolism: Clinical and Experimental, 2015, 64, 1060-1067.	3.4	27
79	Philip E. Cryer, MD: Seminal Contributions to the Understanding of Hypoglycemia and Glucose Counterregulation and the Discovery of HAAF (Cryer Syndrome). Diabetes Care, 2015, 38, 2193-2199.	8.6	23
80	Lack of Racial Disparity in Incident Prediabetes and Glycemic Progression Among Black and White Offspring of Parents With Type 2 Diabetes: The Pathobiology of Prediabetes in a Biracial Cohort (POP-ABC) Study. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E1078-E1087.	3.6	45
81	Potential effects of racial and ethnic disparities in meeting Medicare medication therapy management eligibility criteria. Journal of Pharmaceutical Health Services Research, 2014, 5, 109-118.	0.6	5
82	Glucoregulatory function among African Americans and European Americans with normal or pre-diabetic hemoglobin A1c levels. Metabolism: Clinical and Experimental, 2014, 63, 767-772.	3.4	13
83	Potential health implications of racial and ethnic disparities in meeting MTM eligibility criteria. Research in Social and Administrative Pharmacy, 2014, 10, 106-125.	3.0	9
84	Effects of medicare part d on disparity implications of medication therapy management eligibility criteria. American Health and Drug Benefits, 2014, 7, 346-58.	0.5	4
85	Recruitment strategies and yields for the Pathobiology of Prediabetes in a Biracial Cohort: a prospective natural history study of incident dysglycemia. BMC Medical Research Methodology, 2013, 13, 64.	3.1	17
86	Hypoglycemia in Patients with Type 1 Diabetes: Epidemiology, Pathogenesis, and Prevention. Current Diabetes Reports, 2013, 13, 669-678.	4.2	43
87	Pathobiology of Prediabetes in a Biracial Cohort (POP-ABC) Study: Baseline Characteristics of Enrolled Subjects. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 120-128.	3.6	27
88	Pathobiology of Prediabetes in a Biracial Cohort (POP-ABC): Retention Strategies. Diabetes Care, 2013, 36, e50-e51.	8.6	1
89	Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society. Diabetes Care, 2013, 36, 1384-1395.	8.6	1,125
90	Disparity implications of the Medicare medication therapy management eligibility criteria: a literature review. Expert Review of Pharmacoeconomics and Outcomes Research, 2013, 13, 201-216.	1.4	9

#	Article	IF	Citations
91	Comment on: Maruthur et al. Does Genetic Ancestry Explain Higher Values of Glycated Hemoglobin in African Americans? Diabetes 2011;60:2434-2438. Diabetes, 2012, 61, e1-e1.	0.6	1
92	Metabolomic Prediction of Diabetes and Cardiovascular Risk. Medical Principles and Practice, 2012, 21, 401-403.	2.4	10
93	Predicting Diabetes: Our Relentless Quest for Genomic Nuggets. Diabetes Care, 2012, 35, 193-195.	8.6	13
94	Ethnic Disparity in Hemoglobin A1c Levels Among Normoglycemic Offspring of Parents with Type 2 Diabetes Mellitus. Endocrine Practice, 2012, 18, 356-362.	2.1	23
95	Preventing diabetes mellitus in developing countries. Nature Reviews Endocrinology, 2012, 8, 557-562.	9.6	34
96	Leukocyte count and cardiometabolic risk among healthy participants with parental type 2 diabetes: the Pathobiology of Prediabetes in a Biracial Cohort study. Ethnicity and Disease, 2012, 22, 445-50.	2.3	7
97	American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan. Endocrine Practice, 2011, 17, 1-53.	2.1	387
98	Pitfalls in the use of HbA1c as a diagnostic test. Nature Reviews Endocrinology, 2011, 7, 1-1.	9.6	2
99	Five Ms of adherence. Journal of Diabetes, 2011, 3, 169-171.	1.8	10
100	Comorbidities of Diabetes and Hypertension: Mechanisms and Approach to Target Organ Protection. Journal of Clinical Hypertension, 2011, 13, 244-251.	2.0	333
101	Dissociation Between Cardiovascular Risk Markers and Clinical Outcomes in African Americans: Need for Greater Mechanistic Insight. Current Cardiovascular Risk Reports, 2011, 5, 200-206.	2.0	4
102	Prediabetes as a Therapeutic Target. Clinical Chemistry, 2011, 57, 215-220.	3.2	37
103	TCF7L2 Polymorphism, Weight Loss and Proinsulinâ^¶Insulin Ratio in the Diabetes Prevention Program. PLoS ONE, 2011, 6, e21518.	2.5	27
104	Pathobiology of Prediabetes in a Biracial Cohort (POP-ABC): design and methods. Ethnicity and Disease, 2011, 21, 33-9.	2.3	27
105	Disparity Implications of Medicare Eligibility Criteria for Medication Therapy Management Services. Health Services Research, 2010, 45, 1061-1082.	2.0	36
106	Principles and Practice of Nonpharmacological Interventions to Reduce Cardiometabolic Risk. Medical Principles and Practice, 2010, 19, 167-175.	2.4	49
107	Pitfalls in the use of HbA1c as a diagnostic test: the ethnic conundrum. Nature Reviews Endocrinology, 2010, 6, 589-593.	9.6	110
108	Fasting Plasma Leptin Level Is a Surrogate Measure of Insulin Sensitivity. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 3836-3843.	3.6	43

#	Article	IF	Citations
109	The role of antipsychotic agents in the development of diabetes mellitus. Nature Clinical Practice Endocrinology and Metabolism, 2009, 5, 22-23.	2.8	1
110	Glucoregulatory Physiology in Subjects with Low-Normal, High-Normal, or Impaired Fasting Glucose. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2031-2036.	3.6	28
111	Dynamic Responses to Leptin Secretagogues in Lean, Obese, and Massively Obese Men and Women. Hormone Research, 2008, 70, 174-181.	1.8	6
112	Sex Differences in Diabetes Risk and the Effect of Intensive Lifestyle Modification in the Diabetes Prevention Program. Diabetes Care, 2008, 31, 1416-1421.	8.6	104
113	Understanding and Identifying Pre-diabetes â€“ Can We Halt the Diabetes Epidemic?. European Endocrinology, 2008, 4, 16.	1.5	3
114	Barriers to Achieving Optimal Glycemic Control in a Multi-Ethnic Society: A US Focus. Current Diabetes Reviews, 2006, 2, 285-293.	1.3	18
115	Primary prevention of type-2 diabetes in developing countries. Journal of the National Medical Association, 2006, 98, 415-9.	0.8	29
116	Primary Prevention of Cardiovascular Disease in Pre-Diabetes. Diabetes Care, 2005, 28, 971-972.	8.6	15
117	Inhibition of Cortisol Biosynthesis Decreases Circulating Leptin Levels in Obese Humans. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5333-5335.	3.6	29
118	Epidemiology of Type 2 Diabetes: Focus on Ethnic Minorities. Medical Clinics of North America, 2005, 89, 949-975.	2.5	114
119	Hypoglycemia in Type 1 Diabetes Mellitus. Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders, 2004, 3, 91-103.	1.8	35
120	Leptin Response to Glucocorticoid Occurs at Physiological Doses and Is Abolished by Fasting. Obesity, 2003, 11, 232-237.	4.0	24
121	Ethnic disparities in type 2 diabetes: pathophysiology and implications for prevention and management. Journal of the National Medical Association, 2003, 95, 774, 779-89.	0.8	44
122	Preventing diabetes-related morbidity and mortality in the primary care setting. Journal of the National Medical Association, 2002, 94, 549-60.	0.8	25
123	Thyroid Function during Pregnancy. Clinical Chemistry, 1999, 45, 2250-2258.	3.2	133
124	Reproducibility of Fasting Plasma Leptin Concentration in Lean and Obese Humans. Endocrine Research, 1999, 25, 1-10.	1.2	17
125	Basal and Stimulated Plasma Leptin in Diabetic Subjects. Obesity, 1999, 7, 537-544.	4.0	17
126	Hyperleptinemia in Patients with End-Stage Renal Disease Undergoing Continuous Ambulatory Peritoneal Dialysis. Peritoneal Dialysis International, 1998, 18, 34-40.	2.3	54

#	Article	IF	Citations
127	Increased Plasma Leptin Concentration in End-Stage Renal Disease1. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 847-850.	3.6	190
128	Robust Leptin Secretory Responses to Dexamethasone in Obese Subjects*. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3230-3233.	3.6	123
129	Pathophysiology of Type 2 Diabetes and Modes of Action of Therapeutic Interventions. Archives of Internal Medicine, 1997, 157, 1802.	3.8	71
130	Cerebral transport and metabolism of 1-11C-D-glucose during stepped hypoglycemia. Annals of Neurology, 1995, 38, 599-609.	5.3	23
131	Increased Salivary Concentration of Human Epidermal Growth Factor in Patients Undergoing CAPD. Peritoneal Dialysis International, 1991, 11, 270-273.	2.3	5